Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) EBIT: 2020-2025

Historic EBIT for iSpecimen (ISPC) over the last 6 years, with Sep 2025 value amounting to -$2.8 million.

  • iSpecimen's EBIT fell 65.96% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.1 million, marking a year-over-year decrease of 24.31%. This contributed to the annual value of -$12.7 million for FY2024, which is 13.96% down from last year.
  • Latest data reveals that iSpecimen reported EBIT of -$2.8 million as of Q3 2025, which was down 55.38% from -$1.8 million recorded in Q2 2025.
  • In the past 5 years, iSpecimen's EBIT registered a high of -$942,644 during Q1 2021, and its lowest value of -$5.8 million during Q4 2024.
  • For the 3-year period, iSpecimen's EBIT averaged around -$2.7 million, with its median value being -$2.5 million (2023).
  • As far as peak fluctuations go, iSpecimen's EBIT crashed by 244.27% in 2021, and later soared by 45.40% in 2025.
  • Over the past 5 years, iSpecimen's EBIT (Quarterly) stood at -$2.0 million in 2021, then fell by 7.35% to -$2.1 million in 2022, then slumped by 34.06% to -$2.9 million in 2023, then crashed by 103.43% to -$5.8 million in 2024, then crashed by 65.96% to -$2.8 million in 2025.
  • Its last three reported values are -$2.8 million in Q3 2025, -$1.8 million for Q2 2025, and -$1.6 million during Q1 2025.